But they aren't enough to overcome the headwind of the company's ongoing patent legislation.
Good numbers, but they take a back seat to the legal battle over Bausch drug Xifaxan.
Management didn't provide any update on timing for when the remaining 88% of BLCO that Bausch Health owns will be sold off.
Management now expects companywide EBITDA in a range of $3.01 to $3.11 billion, versus an earlier range of $3.0 to $3.15 billion.
As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.
Persons:
Bausch, Xifaxan, BCH's Bausch, companywide, Jim Cramer's, Jim Cramer, Jim, Timothy Fadek
Organizations:
Health, Revenue, Pharmaceuticals, Norwich Pharmaceuticals, D.C, Norwich, FDA, XIFAXAN, Management didn't, Bausch Health, Management, CNBC, International Pharmaceutical, Bloomberg, Getty Images Bloomberg, Getty
Locations:
New York, U.S, Interphex